AIHA Announces New 2025-2026 Board Members, Prepares for Inaugural Strategic Meeting in New Orleans, LA

FALLS CHURCH, Va.--(BUSINESS WIRE)--AIHA, the association for occupational and environmental health and safety (OEHS) professionals, inducted its new Board of Directors for the 2025-2026 term during its annual business meeting held during the AIHA Connect 2025 conference in Kansas City, MO. The AIHA Board will commence its first Strategic Planning meeting in July in New Orleans, LA, site of AIHA Connect 2026.
The 2025-2026 Board of Directors includes officers:
President: Bradley S. King, PhD, MPH, CIH
President-Elect: Nancy M. McClellan, MPH, CIH, CHMM
Vice President: Cheryl Marcham, PhD, CIH, CSP, CHMM, FAIHA
Past President: Nicole M.H. Greeson, MS, CIH
Secretary: Justine Parker, CIH, CSP, CPH, CHMM
Treasurer: Lucinette Alvarado Rivera, CIH
Treasurer-Elect: Eric R. White, MPH, CIH, CSP
AIHA members serving as directors-at-large include:
Isabel Bacarella, MPH, CIH, CSP
Vanessa A. Brady, MS, CIH, CSP
Matthew M. Dahm, PhD
John R. Moore III, CIH, CSP
Bradley Rodgers, MS, MBA, CIH, CSP
Amy Snow, CIH
'Each member of AIHA's Board of Directors contributes their own unique perspectives and experiences,' said Lawrence Sloan, CEO of AIHA. 'Their knowledge, expertise, dedication, and passion support our mission of promoting and protecting worker health and will contribute significantly to our efforts as we continue to navigate the evolving landscape of occupational health and safety.'
Sloan expressed his appreciation for the invaluable contributions made to AIHA by the outgoing Board members: Dina M. Siegel, CIH, CSP, CBSP, FAIHA, former past president; Pamela A. Kostle, CIH, FAIHA, former secretary; and Bryan Seal, PhD, CIH, CSP, CHMM, REHS; former director-at-large. 'Our Board members volunteer significant time and energy during their tenures, and for that we are grateful,' said Sloan. 'Their contributions to AIHA will have lasting effects on our organization and the health and safety of workers and communities around the world.'
Details of Newly Elected 2025-2026 Board Members:
Cheryl (Cheri) Marcham, PhD, CIH, CSP, CHMM, FAIHA, was elected Vice President. Marcham has previously served on the board as a director-at-large. She has volunteered with several AIHA groups including the Indoor Environmental Quality Committee, Academic Accreditation Panel, Conference Program Committee, Real-Time Detection Systems Committee, and more. She has authored or contributed to several AIHA publications, including serving most recently as Project Team Leader for the Aerosolized Infectious Agents Guidance Document and as Project Team member of the Hierarchy of Controls White Paper, which received the 2024 AIHA President's Award. Marcham is Associate Professor and Program Chair at Embry-Riddle Aeronautical University.
Isabel Bacarella, MPH, CIH, CSP, was elected director-at-large. Bacarella has been a member of AIHA since 2010 and previously served as Chair of the Women in Industrial Hygiene Committee, President of the Gulf Coast Local Section, and member of the AIHA Career and Employment Services Group. In 2016, she received the AIHA Outstanding Volunteer Member Award. Bacarella currently works as Manager of Gas Transmission & Midstream (GRM) Safety Operations at Enbridge in Houston, TX.
Amy Snow, CIH, was elected director-at-large. Snow has served as Chair of the Healthcare Working Group, Lead of the Hazardous Drug Subcommittee (publishing the AIHA Hazardous Drug Surface Contamination Guidance Document), and Secretary of the Carolinas Local Section. Snow has also served on the Occupational and Environmental Epidemiology Volunteer Group. She currently works for Trinity - SafeBridge Consultants as a Managing Industrial Hygienist.
Justine Parker, CIH, CSP, CPH, CHMM and Eric R. White, MPH, CIH, CSP moved from director-at-large roles on the Board to the officer positions of secretary and treasurer respectively. AIHA appreciates their continued support.
About AIHA
AIHA is the association for scientists and professionals committed to preserving and ensuring occupational and environmental health and safety (OEHS) in the workplace and community. Founded in 1939, AIHA supports worker health and safety through our expertise, networks, comprehensive education programs, and other products and services that help companies maintain the highest professional and competency standards. AIHA serves as a resource for those employed across the public and private sectors and the communities in which they work. For more information visit https://aiha.org

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

Yahoo

13-06-2025

• Yahoo

Keymed Biosciences Announces the Latest Clinical Trial Results of CM336 Published in the New England Journal of Medicine

CHENGDU, China, June 12, 2025 /PRNewswire/ -- Keymed Biosciences Inc. (HKEX: 02162) today announced that Prof. Jun Shi's research team from the Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences (Institute of Hematology, Chinese Academy of Medical Sciences) has recently published a research report titled "BCMA-Targeted T-Cell Engager for Autoimmune Hemolytic Anemia after CD19 CAR T-Cell Therapy" in the New England Journal of Medicine (NEJM), which has reported for the first time globally the research data on a BCMA x CD3 bispecific antibody treatment for patients with refractory autoimmune hemolytic anemia (AIHA). The study results showed that two patients experienced rapid disease improvement after the administration of CM336, achieving partial remission on days 13 and 19, respectively. Hemoglobin levels returned to normal on days 17 and 21, respectively, while reticulocyte counts, lactate dehydrogenase, and indirect bilirubin levels significantly decreased. Before receiving treatment with CM336, both patients had undergone multiple treatment regimens, including glucocorticoids, splenectomy, anti-CD20 antibodies, BTK inhibitors, and CD19 CAR-T cell therapies, but their disease eventually recurred or progressed to refractory status. The latest assessment results after 6 months post-starting CM336 showed that both patients remained in sustained remission without immunosuppressive therapies or transfusions. No cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), or infection events occurred during the entire treatment and follow-up period. The overall study showed that CM336 had demonstrated positive efficacy signals in treating patients with relapsed/refractory AIHA who had previously received multiple therapies, with rapid disease control and sustained remission lasting over half a year, while also exhibiting good safety profile, potentially making it an innovative treatment option for development in this disease. About CM336CM336 is a BCMA x CD3 bispecific antibody that can simultaneously target and identify and specifically bind both BCMA on the surface of target cells and the CD3 receptors on the surface of T cells to recruit immune T cells to the vicinity of the target cells, thereby inducing T-cell dependent cellular cytotoxicity (TDCC) to eliminate the target cells. As of the date of this announcement, the Phase II clinical study of CM336 for the treatment of primary light-chain amyloidosis has been approved by the Center for Drug Evaluation of the National Medical Products Administration and will commence clinical trials shortly. About Keymed BiosciencesKeymed Biosciences Inc. (HKEX: 02162) is a biotech company focused on the urgent unmet clinical needs, and committed to providing high-quality, affordable, innovative therapies for patients in China and overseas. Keymed was founded by medical and scientific experts who have strong experience in the transformation of scientific and technological achievements to commercialization at home and abroad. View original content: SOURCE Keymed Biosciences

Yahoo

13-06-2025

• Yahoo

Keymed Biosciences Announces the Latest Clinical Trial Results of CM336 Published in the New England Journal of Medicine

CHENGDU, China, June 12, 2025 /PRNewswire/ -- Keymed Biosciences Inc. (HKEX: 02162) today announced that Prof. Jun Shi's research team from the Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences (Institute of Hematology, Chinese Academy of Medical Sciences) has recently published a research report titled "BCMA-Targeted T-Cell Engager for Autoimmune Hemolytic Anemia after CD19 CAR T-Cell Therapy" in the New England Journal of Medicine (NEJM), which has reported for the first time globally the research data on a BCMA x CD3 bispecific antibody treatment for patients with refractory autoimmune hemolytic anemia (AIHA). The study results showed that two patients experienced rapid disease improvement after the administration of CM336, achieving partial remission on days 13 and 19, respectively. Hemoglobin levels returned to normal on days 17 and 21, respectively, while reticulocyte counts, lactate dehydrogenase, and indirect bilirubin levels significantly decreased. Before receiving treatment with CM336, both patients had undergone multiple treatment regimens, including glucocorticoids, splenectomy, anti-CD20 antibodies, BTK inhibitors, and CD19 CAR-T cell therapies, but their disease eventually recurred or progressed to refractory status. The latest assessment results after 6 months post-starting CM336 showed that both patients remained in sustained remission without immunosuppressive therapies or transfusions. No cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), or infection events occurred during the entire treatment and follow-up period. The overall study showed that CM336 had demonstrated positive efficacy signals in treating patients with relapsed/refractory AIHA who had previously received multiple therapies, with rapid disease control and sustained remission lasting over half a year, while also exhibiting good safety profile, potentially making it an innovative treatment option for development in this disease. About CM336CM336 is a BCMA x CD3 bispecific antibody that can simultaneously target and identify and specifically bind both BCMA on the surface of target cells and the CD3 receptors on the surface of T cells to recruit immune T cells to the vicinity of the target cells, thereby inducing T-cell dependent cellular cytotoxicity (TDCC) to eliminate the target cells. As of the date of this announcement, the Phase II clinical study of CM336 for the treatment of primary light-chain amyloidosis has been approved by the Center for Drug Evaluation of the National Medical Products Administration and will commence clinical trials shortly. About Keymed BiosciencesKeymed Biosciences Inc. (HKEX: 02162) is a biotech company focused on the urgent unmet clinical needs, and committed to providing high-quality, affordable, innovative therapies for patients in China and overseas. Keymed was founded by medical and scientific experts who have strong experience in the transformation of scientific and technological achievements to commercialization at home and abroad. View original content: SOURCE Keymed Biosciences Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

CBS News

05-06-2025

• CBS News

Colorado State Patrol says trucker's brakes failed, causing I-70 crash that hurt 5 people

Colorado police have determined how a crash unfolded Wednesday that shut down I-70 for several hours and left multiple people injured. According to CSP, a Freightliner semi-truck with a trailer, driven by Leon Gamble of Texas, lost its brakes near the Eisenhower Tunnel while driving west along the interstate. The front of the truck crashed into the back of another Freightliner truck, and both vehicles veered off the left side of the road. Colorado State Patrol Authorities said the second truck rolled over and came to rest in the median on its passenger side. The trailer of the first truck struck a Toyota Rav4 heading east, and then reportedly came to a stop against a Toyota Tacoma. Authorities said five people were taken to the hospital for treatment. Four of those suffered minor injuries, but the driver of the second Freightliner suffered life-threatening injuries. CSP said the driver of the Tacoma was not injured. They issued Gamble a citation for careless driving causing bodily injury. The crash remains under investigation. Authorities asked anyone who witnessed the crash and hasn't spoken with investigators to call CSP dispatch at (970) 249-4392 and provide their information so an investigator can contact them.